Discovery of coumaric acid derivatives hinted by coastal marine source to seek for uric acid lowering agents

In this work, a series of novel compounds Spartinin C1-C24 were screened, synthesised and evaluated for inhibiting xanthine oxidase thus lowering serum uric acid level. The backbones were derived from the components of coastal marine source Spartina alterniflora and marketed drugs. The top hits Spartinin C10 & C22 suggested high inhibition percentages (78.54 and 93.74) at 10 mu M dosage, which were higher than the positive control Allopurinol. They were low cytotoxic onto human normal hepatocyte cells. Treatment with Spartinin C10 could lower the serum uric acid level to 440.0 mu M in the hyperuricemic model mice (723.0 mu M), comparable with Allopurinol (325.8 mu M). Spartinin C10 was more appreciated than Allopurinol on other serum indexes. The preliminary pharmacokinetics evaluation indicated that the rapid absorption, metabolism and elimination of Spartinin C10 should be further improved. The discovery of pharmaceutical molecules from coastal marine source here might inspire the inter-disciplinary investigations on public health.

Automated summary

In this study, a series of novel compounds Spartinin C1-C24 were screened, synthesized, and evaluated for their ability to inhibit xanthine oxidase and lower serum uric acid levels. The top hits, Spartinin C10 and C22, showed high inhibition percentages (78.54% and 93.74%) at a dosage of 10 μM, surpassing the positive control Allopurinol. They exhibited low cytotoxicity towards human normal hepatocyte cells. Spartinin C10 treatment effectively reduced serum uric acid levels in hyperuricemic model mice and showed comparable results to Allopurinol.